Surgical Science Sweden AB (SUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surgical Science Sweden AB (SUS) has a cash flow conversion efficiency ratio of 0.017x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr72.89 Million ≈ $7.84 Million USD) by net assets (Skr4.27 Billion ≈ $459.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Surgical Science Sweden AB to measure how many days the company can operate on defensive assets alone.
Surgical Science Sweden AB - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Surgical Science Sweden AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Surgical Science Sweden AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surgical Science Sweden AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JTC Inc
KQ:950170
|
0.059x |
|
Allgeier SE
XETRA:AEIN
|
0.070x |
|
Shaniv
TA:SHAN
|
0.112x |
|
Wei Chih Steel Industrial Co Ltd
TW:2028
|
0.012x |
|
Zueblin Immobilien Holding AG
SW:ZUBN
|
0.019x |
|
Tavia Acquisition Corp. Ordinary Shares
NASDAQ:TAVI
|
-0.001x |
|
Korea Alcohol Industrial Co. Ltd
KQ:017890
|
0.025x |
|
PBA Holdings Bhd
KLSE:5041
|
0.093x |
Annual Cash Flow Conversion Efficiency for Surgical Science Sweden AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Surgical Science Sweden AB from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Surgical Science Sweden AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr4.27 Billion ≈ $459.85 Million |
Skr79.80 Million ≈ $8.59 Million |
0.019x | -34.29% |
| 2024-12-31 | Skr4.83 Billion ≈ $519.64 Million |
Skr137.22 Million ≈ $14.77 Million |
0.028x | -48.18% |
| 2023-12-31 | Skr4.35 Billion ≈ $467.61 Million |
Skr238.29 Million ≈ $25.64 Million |
0.055x | +79.42% |
| 2022-12-31 | Skr4.24 Billion ≈ $455.91 Million |
Skr129.49 Million ≈ $13.93 Million |
0.031x | +180.37% |
| 2021-12-31 | Skr3.59 Billion ≈ $385.81 Million |
Skr39.08 Million ≈ $4.21 Million |
0.011x | -79.95% |
| 2020-12-31 | Skr427.05 Million ≈ $45.96 Million |
Skr23.23 Million ≈ $2.50 Million |
0.054x | -60.43% |
| 2019-12-31 | Skr401.68 Million ≈ $43.23 Million |
Skr55.20 Million ≈ $5.94 Million |
0.137x | +58.62% |
| 2018-12-31 | Skr79.38 Million ≈ $8.54 Million |
Skr6.88 Million ≈ $740.18K |
0.087x | -6.64% |
| 2017-12-31 | Skr85.52 Million ≈ $9.20 Million |
Skr7.94 Million ≈ $854.15K |
0.093x | -84.49% |
| 2016-12-31 | Skr22.40 Million ≈ $2.41 Million |
Skr13.40 Million ≈ $1.44 Million |
0.598x | +56.33% |
| 2015-12-31 | Skr19.60 Million ≈ $2.11 Million |
Skr7.50 Million ≈ $807.12K |
0.383x | -- |
About Surgical Science Sweden AB
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquis… Read more